{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:52:58Z","timestamp":1774533178028,"version":"3.50.1"},"reference-count":196,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.atherosclerosis.2014.09.026","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T17:27:39Z","timestamp":1412098059000},"page":"319-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Combination therapy in dyslipidemia: Where are we now?"],"prefix":"10.1016","volume":"237","author":[{"given":"Alberico L.","family":"Catapano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnne M.","family":"Foody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan \u2013 2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib4","series-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib8","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2014.09.026_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.18.S1.1","article-title":"American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib11","series-title":"An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia","author":"International Atherosclerosis Society (IAS)","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib13","series-title":"Recommendations for Patient-centered Treatment of Dyslipidemia","author":"The National Lipid Association","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib14","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.amjcard.2010.11.006","article-title":"Achieving optimal lipid goals in patients with coronary artery disease","volume":"107","author":"Karalis","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib19","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib20","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia","volume":"97","author":"Bays","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.amjcard.2013.02.005","article-title":"Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the clinical outcomes utilizing revascularization and aggressive drug evaluation [COURAGE] trial)","volume":"111","author":"Maron","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib26","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2009.06.036","article-title":"Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study","volume":"54","author":"Lee","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib28","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib30","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2014.09.026_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib35","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.amjcard.2010.01.363","article-title":"Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial","volume":"105","author":"Holme","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population","volume":"168","author":"Blazing","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database","volume":"51","author":"Barter","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jacl.2010.01.007","article-title":"Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients","volume":"4","author":"Foody","year":"2010","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib39","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","article-title":"Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1741826710397100","article-title":"Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey","volume":"19","author":"Park","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2009.01.001","article-title":"Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy","volume":"157","author":"Airan-Javia","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib45","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report","volume":"106","author":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib46","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2003.9.s1.9","article-title":"Overview of pharmacologic therapy for the treatment of dyslipidemia","volume":"9","author":"Lipsy","year":"2003","journal-title":"J.\u00a0Manag. Care Pharm."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1185\/030079908X280446","article-title":"Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia","volume":"24","author":"Florentin","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib49","series-title":"Zetia\u00ae (Ezetemibe) Tablets Prescribing Information","author":"Merck Sharp and Dohme Corp","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe plus statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/clp.12.88","article-title":"The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups","volume":"8","author":"Catapano","year":"2013","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib52","series-title":"Vytorin\u00ae (Ezetimibe\/simvastatin) Tablets Prescribing Information","author":"Merck Sharp and Dohme Corp","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib53","series-title":"Liptruzet\u00ae (Ezetimibe and Atorvastatin) Tablets Prescribing Information","author":"Merck Sharp and Dohme Corp","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib54","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","volume":"11","author":"Bays H.","year":"2002","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib55","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.amjcard.2013.08.031","article-title":"Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia","volume":"112","author":"Bays","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib58","doi-asserted-by":"crossref","first-page":"d548","DOI":"10.1136\/bmj.d548","article-title":"Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11883-012-0295-3","article-title":"Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?","volume":"15","author":"Ridker","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib62","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4070\/kcj.2011.41.11.641","article-title":"The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis","volume":"41","author":"Lee","year":"2011","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib63","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib64","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib65","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib66","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib67","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11883-009-0075-x","article-title":"Therapeutic options to further lower C-reactive protein for patients on statin treatment","volume":"12","author":"Joshi","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib69","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2010.05.059","article-title":"Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials","volume":"56","author":"Costanzo","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib71","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/fca.11.44","article-title":"Questioning the predictive role of carotid intima-media thickness","volume":"7","author":"Costanzo","year":"2011","journal-title":"Future Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1472-8206.2003.00233.x","article-title":"Rationale, design and methods of the CASHMERE study","volume":"18","author":"Simon","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib73","series-title":"Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women. A Randomised Evaluation of Atorvastatin versus Placebo (CASHMERE) (NCT#00163163)","author":"Pfizer","year":"2007"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib74","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib76","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib77","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib78","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/2047487312451539","volume":"20","author":"Ikeda","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib79","first-page":"834","article-title":"Trends in baseline carotid intima-media thickness (cIMT) and LDL-C levels in statin LDL-C lowering studies during 1988-2008","volume":"32","author":"Davidson","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib80","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacl.2008.06.011","article-title":"Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: should ezetimibe move to the \u201cBack of the Line\u201d as a therapy for dyslipidemia?","volume":"2","author":"Toth","year":"2008","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib82","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.jacc.2008.11.002","article-title":"Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?","volume":"52","author":"Stein","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib83","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib84","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/heartjnl-2013-303926","article-title":"MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study","volume":"99","author":"Sibley","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib85","first-page":"S376","article-title":"Abstract 685: comparative effect of statins vs. Niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: the NIA plaque study","volume":"120","author":"Sibley","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib86","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(12)60441-3","article-title":"Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data","volume":"379","author":"Lorenz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib87","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1093\/eurheartj\/eht213","article-title":"Beyond statins: what to expect from add-on lipid regulating therapy?","volume":"34","author":"Laufs","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib88","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib90","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib91","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MOL.0b013e32834b4994","article-title":"Statins and the risk of new-onset diabetes: a review of recent evidence","volume":"22","author":"Preiss","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib92","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib93","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib94","series-title":"FDA Expands Advice on Statin Risks","author":"Food and Drug Administration (FDA)","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib95","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib96","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib97","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2014.09.026_bib99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2013.06.006","article-title":"HPS2-THRIVE results: bad for niacin\/laropiprant, good for ezetimibe?","volume":"229","author":"Masana","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib100","series-title":"Niaspan\u00ae (Niacin Extended-release) Tablets Prescribing Information","author":"AbbVie Inc","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib101","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib102","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib104","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib105","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib106","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J.\u00a0Cardiovasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib107","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib108","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib109","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","article-title":"Safety of aggressive lipid management","volume":"49","author":"Davidson","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib110","series-title":"Tricor\u00ae (Fenofibrate) Tablets Prescribing Information","author":"AbbVie Inc","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib111","series-title":"Fenoglide\u00ae (Fenofibrate) Tablets Prescribing Information","author":"Santarus, Inc","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib112","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib113","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.1992.00400190041009","article-title":"The lipid research clinics coronary primary prevention trial. Results of 6 years of post-trial follow-up","volume":"152","author":"The Lipid Research Clinics Investigators","year":"1992","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib114","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/phar.1317","article-title":"Lower risk of major cardiovascular events associated with adherence to colesevelam HCI","volume":"33","author":"Ye","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib115","series-title":"QUESTRAN\u00ae LITE (Cholestyramine Resin) Prescribing Information","author":"Aspen Pharma","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib116","series-title":"WELCHOL\u00ae (Colesevelam Hydrochloride) Prescribing Information","author":"Daiichi Sankyo","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib117","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1742-1241.2012.02964.x","article-title":"Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks","volume":"66","author":"Toth","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib118","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib119","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/1745509X.3.6.691","article-title":"Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65\u201374 and 75 years and older","volume":"3","author":"Robinson","year":"2007","journal-title":"Aging Health."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib120","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials","volume":"359","author":"Peto","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib121","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes - 2013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib122","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2012.05.007","volume":"223","author":"Perk","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib124","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","article-title":"Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Robinson","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib126","series-title":"Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia (Clinical guideline 71)","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib127","first-page":"I","article-title":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib128","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.CIR.0000112379.88385.67","article-title":"Clinical management of metabolic syndrome: report of the American Heart Association\/National Heart, Lung, and Blood Institute\/American Diabetes Association conference on scientific issues related to management","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib130","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, LUNG, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib131","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.amjcard.2009.05.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)","volume":"103","author":"Robinson","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib132","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jacl.2011.06.004","volume":"5","author":"Robinson","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib133","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2362.2009.02126.x","article-title":"Fluvastatin\/fenofibrate vs. simvastatin\/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles","volume":"39","author":"Winkler","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/met.2010.0068","article-title":"Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome","volume":"9","author":"Bays","year":"2011","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib135","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x","article-title":"Lipid-altering efficacy and safety profile of combination therapy with ezetimibe\/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials","volume":"13","author":"Leiter","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib137","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/dc10-0320","article-title":"Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial","volume":"33","author":"Ruggenenti","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib138","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacl.2008.01.001","article-title":"Effect of ezetimibe\/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes","volume":"2","author":"Weinstock","year":"2008","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib139","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1463-1326.2007.00725.x","article-title":"Efficacy of ezetimibe\/simvastatin 10\/20 and 10\/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus","volume":"9","author":"Constance","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib140","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib141","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1479164111406457","article-title":"Achievement of recommended lipid and lipoprotein levels with combined ezetimibe\/statin therapy versus statin alone in patients with and without diabetes","volume":"8","author":"Guyton","year":"2011","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib142","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1479164111430715","article-title":"Comparative efficacy and safety of fenofibrate\/pravastatin plus ezetimibe triple therapy and simvastatin\/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease","volume":"9","author":"Farnier","year":"2012","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib143","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2337\/db12-0923","article-title":"The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes","volume":"62","author":"Smushkin","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib144","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/met.2012.0103","article-title":"Colesevelam plus rosuvastatin 5 mg\/day versus rosuvastatin 10 mg\/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose","volume":"11","author":"Florentin","year":"2013","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000327317","article-title":"Lipid abnormalities in patients with chronic kidney disease","volume":"171","author":"Keane","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5551\/jat.12849","article-title":"Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis","volume":"20","author":"Keane","year":"2013","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib147","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib148","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib149","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2013 a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib151","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib152","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib153","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","article-title":"Effect of pravastatin in people with diabetes and chronic kidney disease","volume":"16","author":"Tonelli","year":"2005","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib154","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib156","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib157","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib158","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2008.09.002","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia","volume":"52","author":"van der Graaf","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib159","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2014.09.026_bib160","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib161","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1161\/01.CIR.101.21.2497","article-title":"New insights into the progression of aortic stenosis: implications for secondary prevention","volume":"101","author":"Palta","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib162","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A\u00a0randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib163","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib164","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2012.02.006","article-title":"Non-every day statin administration\u2013a literature review","volume":"23","author":"Elis","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib165","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10\u00a0mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib167","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079905X28872","article-title":"Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias","volume":"21","author":"Wierzbicki","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib168","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/030079907X226267","article-title":"Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin","volume":"23","author":"Gazi","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib169","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.amjmed.2012.09.004","article-title":"The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review","volume":"126","author":"Bitton","year":"2013","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib171","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib172","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with\u00a0statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib173","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib174","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-151-9-200911030-00144","article-title":"Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia","volume":"151","author":"Sharma","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib176","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2261-10-29","article-title":"Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees","volume":"10","author":"Chapman","year":"2010","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib177","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib178","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib179","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ahj.2011.08.012","article-title":"The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives","volume":"162","author":"Sanz","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib180","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib181","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib182","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib183","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib184","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib186","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib187","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib188","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CRD.0b013e31823424be","article-title":"Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia","volume":"20","author":"Ricotta","year":"2012","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib189","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib190","series-title":"FDA Approves New Orphan Drug for Rare Cholesterol Disorder","author":"Food and Drug Administration (FDA)","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib191","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib192","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib193","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3810\/pgm.2012.11.2612","article-title":"Novel strategies for managing dyslipidemia: treatment beyond statins","volume":"124","author":"Ling","year":"2012","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.atherosclerosis.2014.09.026_bib194","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOL.0b013e3283475e00","article-title":"Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism","volume":"22","author":"Niesor","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2014.09.026_bib195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CRD.0000000000000023","article-title":"Anacetrapib: a potential new therapy for dyslipidemia","volume":"22","author":"Robinson","year":"2014","journal-title":"Cardiol. Rev."},{"issue":"25 Pt B","key":"10.1016\/j.atherosclerosis.2014.09.026_bib196","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014014282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014014282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T05:38:18Z","timestamp":1598333898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014014282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":196,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0021915014014282"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.09.026","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in dyslipidemia: Where are we now?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}